Stay updated on FLX475 Dose Escalation Trial in Combination With Pembrolizumab
Sign up to get notified when there's something new on the FLX475 Dose Escalation Trial in Combination With Pembrolizumab page.

Latest updates to the FLX475 Dose Escalation Trial in Combination With Pembrolizumab page
- Check6 days agoChange DetectedAdded a Results Submitted status and expanded the Locations section to include multiple study sites across the United States and Australia. The expanded location list includes Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Kentucky, Maryland, Massachusetts, Michigan, New Mexico, New York, North Carolina, Texas, Washington, Victoria, and Western Australia.SummaryDifference2%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check35 days agoChange DetectedThe page now shows an updated revision label: v3.3.2, replacing the previous v3.2.0.SummaryDifference0.0%

- Check42 days agoChange DetectedThe funding-status notice that previously appeared on the ClinicalTrials.gov page was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check49 days agoChange DetectedEntries for postcodes 70403 and 71004 were updated from Tainan City, Taiwan to Tainan, Taiwan, and the new locations were added.SummaryDifference0.1%

- Check63 days agoChange DetectedMinor administrative update to the study record, such as a new last update timestamp, with no changes to core study design, eligibility criteria, interventions, or primary outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check85 days agoChange DetectedAdded a prominent operating-status notice and a v3.2.0 version tag, replacing the prior v3.1.0 revision.SummaryDifference4%

Stay in the know with updates to FLX475 Dose Escalation Trial in Combination With Pembrolizumab
Enter your email address, and we'll notify you when there's something new on the FLX475 Dose Escalation Trial in Combination With Pembrolizumab page.